The Impact of COVID-19 is included in Human Papillomavirus (HPV) Vaccine Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Human Papillomavirus (HPV) Vaccine Trends and Forecast
The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Human Papillomavirus (HPV) Vaccine by Segment
The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.
Human Papillomavirus (HPV) Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:
• Tetravalent
• Nonavalent
• Bivalent
Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
• Hospital & Retail Pharmacies
• Government Suppliers
• Others
Human Papillomavirus (HPV) Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Human Papillomavirus (HPV) Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-
• Johnson & Johnson
• Xenetic Biosciences
• AstraZeneca
• Merck
• Serum Institute Of India
• Inovio Pharmaceuticals
• Bharat Biotech
• Sanofi
• GlaxoSmithKline
• Novartis
Human Papillomavirus (HPV) Vaccine Market Insights
Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.
North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.
Features of the Global Human Papillomavirus (HPV) Vaccine Market
Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).
Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the human papillomavirus (HPV) vaccine market size?
Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.
Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?
Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?
Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.
Q4. What are the major segments for human papillomavirus (HPV) vaccine market?
Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.
Q5. Who are the key human papillomavirus (HPV) vaccine market companies?
Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:
• Johnson & Johnson
• Xenetic Biosciences
• AstraZeneca
• Merck
• Serum Institute Of India
• Inovio Pharmaceuticals
• Bharat Biotech
• Sanofi
• GlaxoSmithKline
• Novartis
Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?
Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.
Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Human Papillomavirus (Hpv) Vaccine Market, Human Papillomavirus (Hpv) Vaccine Market Size, Human Papillomavirus (Hpv) Vaccine Market Growth, Human Papillomavirus (Hpv) Vaccine Market Analysis, Human Papillomavirus (Hpv) Vaccine Market Report, Human Papillomavirus (Hpv) Vaccine Market Share, Human Papillomavirus (Hpv) Vaccine Market Trends, Human Papillomavirus (Hpv) Vaccine Market Forecast, Human Papillomavirus (Hpv) Vaccine Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
3.3.1: Tetravalent
3.3.2: Nonavalent
3.3.3: Bivalent
3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
3.4.1: Hospital & Retail Pharmacies
3.4.2: Government Suppliers
3.4.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
4.2: North American Human Papillomavirus (HPV) Vaccine Market
4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
4.3: European Human Papillomavirus (HPV) Vaccine Market
4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
4.4: APAC Human Papillomavirus (HPV) Vaccine Market
4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
4.5: ROW Human Papillomavirus (HPV) Vaccine Market
4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Johnson & Johnson
7.2: Xenetic Biosciences
7.3: AstraZeneca
7.4: Merck
7.5: Serum Institute of India
7.6: Inovio Pharmaceuticals
7.7: Bharat Biotech
7.8: Sanofi
7.9: GlaxoSmithKline
7.10: Novartis
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Human Papillomavirus (HPV) Vaccine Market Report.